| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 6.01 MB | Adobe PDF |
Authors
Abstract(s)
A presente dissertação incorpora duas vertentes da Unidade Curricular de Estágio do
Mestrado Integrado em Ciências Farmacêuticas: a vertente de Investigação (Capítulo
I), e de Farmácia Comunitária (Capítulo II).
O Capítulo I diz respeito à revisão sistemática da literatura em que foi realizada uma
análise da farmacoterapia utilizada no tratamento da depressão pós-parto (DPP), e que
se deu privilégio aos tratamentos nos quais os neurosteróides foram utilizados como
tratamento de primeira linha em detrimento das alternativas terapêuticas
convencionais. Sabe-se que a depressão pós-parto é caraterizada pela ocorrência de um
episódio depressivo major no período pós-parto e esta condição clínica afeta cerca de
10 a 15% das mulheres. Os resultados obtidos nesta revisão sistemática permitiram
inferir que nas doentes que necessitam uma resposta rápida devido à gravidade da
doença, o uso de brexanolona para DPP foi considerado vantajoso relativamente às
terapias convencionais. Os ensaios clínicos realizados levaram à aprovação pela Food
and Drug Administration da brexanolona para o tratamento da DPP, marca Zulresso®.
O Capítulo II ilustra a minha experiência durante o estágio curricular em Farmácia
Comunitária, que decorreu entre 3 de fevereiro e 12 de junho de 2020, no concelho de
Esposende, na Farmácia de Apúlia, sob orientação da Dra. Aurélia Oliveira. Tive a
oportunidade de desenvolver as minhas competências interpessoais e de conhecer em
primeira mão o verdadeiro papel de um farmacêutico comunitário, que vai muito além
da dispensa de medicamentos.
This dissertation incorporates two aspects of the Internship Curricular Unit of the Integrated Master in Pharmaceutical Sciences: Research (Chapter I), and Community Pharmacy (Chapter II). Chapter I concerns the systematic review of the literature in which an analysis of the pharmacotherapy used in the treatment of postpartum depression (PPD) was carried out, and that privileges were given to treatments in which neurosteroids were used as first-line treatment to the detriment conventional therapeutic alternatives. It is known that postpartum depression is characterized by the occurrence of a major depressive episode in the postpartum period and this clinical condition affects about 10 to 15% of women. The results obtained in this systematic review allowed to infer that in patients who need a quick response due to the severity of the disease, the use of brexanolone for DPP was considered advantageous in relation to conventional therapies. The clinical trials carried out led to the approval by the Food and Drug Administration of brexanolone for the treatment of DPP, brand Zulresso®. Chapter II illustrated my experience during the curricular internship in Community Pharmacy, which took place between February 3 and June 12, 2020, in the Municipality of Esposende, in the Pharmacy of Apúlia, under the guidance of Dr. Aurélia Oliveira. I had the opportunity to develop as my interpersonal skills and to know first hand or the real public pharmaceutical role, which goes far beyond dispensing medications.
This dissertation incorporates two aspects of the Internship Curricular Unit of the Integrated Master in Pharmaceutical Sciences: Research (Chapter I), and Community Pharmacy (Chapter II). Chapter I concerns the systematic review of the literature in which an analysis of the pharmacotherapy used in the treatment of postpartum depression (PPD) was carried out, and that privileges were given to treatments in which neurosteroids were used as first-line treatment to the detriment conventional therapeutic alternatives. It is known that postpartum depression is characterized by the occurrence of a major depressive episode in the postpartum period and this clinical condition affects about 10 to 15% of women. The results obtained in this systematic review allowed to infer that in patients who need a quick response due to the severity of the disease, the use of brexanolone for DPP was considered advantageous in relation to conventional therapies. The clinical trials carried out led to the approval by the Food and Drug Administration of brexanolone for the treatment of DPP, brand Zulresso®. Chapter II illustrated my experience during the curricular internship in Community Pharmacy, which took place between February 3 and June 12, 2020, in the Municipality of Esposende, in the Pharmacy of Apúlia, under the guidance of Dr. Aurélia Oliveira. I had the opportunity to develop as my interpersonal skills and to know first hand or the real public pharmaceutical role, which goes far beyond dispensing medications.
Description
Keywords
Brexanolona Depressão Pós-Parto Ensaios Clínicos Farmácia Comunitária Revisão Sistemática